BioMarin’s Vimizim Secures Broad Label In Morquio A Syndrome
This article was originally published in The Pink Sheet Daily
Executive Summary
No limits on age or disease severity of patients appear in elosulfase alfa labeling; agency reviewers had raised the issue of baseline function at a November advisory committee meeting.